"The approval is for R&D projects involving clinical trials (phase I, II and III) to develop new drugs for neglected diseases of tropical regions," Minister of State, Prime Minister's Office Prithvi Raj Chavan told reporters after a meeting of the Cabinet Committee on Economic Affairs.
He said an amount of Rs 45 crore has been earmarked during the 11th five year plan to help the pharma industry and the amount could be increased as the programme develops.
"It would help in developing new drugs for the neglected diseases such a tuberculosis, malaria, kala-azar, filariasis, which are still a big threat in the Indian sub-continent," Chauhan said.
The R&D programme is being conducted under the Drugs and Pharmaceutical Research Programme of Department of Science and Technology, he added.
The department has been implementing the Drugs and Pharmaceuticals Research Programme (DPRP) since 1994-95 as a plan programme to support the pharma industry, institutional collaborative R&D projects and infrastructure.
In 2004-05, the programme started extending soft loans to pharma industry to the tune of 70 per cent of the total cost at an interest rate of 3 per cent with a 10 year repayment period beginning from the end of the project duration.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
